Oxonc Development LP, of Seoul, South Korea, reported that Study OO-1201, a phase II, open-label, single-arm trial testing crizotinib in East Asian patients with ROS1-positive metastatic non-small-cell lung cancer, met its primary objective of demonstrating an overall response rate of 69 percent.